Alto Neuroscience ANRO Fair Value Measurement Disclosure
Fair Value Measurement Disclosure at other companies
Other financials
Where this comes from
Reported directly by Alto Neuroscience in its filing.
Tagged under the XBRL concept us-gaap:FinancialLiabilitiesFairValueDisclosure.
The official record: Alto Neuroscience’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alto Neuroscience's fair value measurement disclosure.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alto Neuroscience's fair value measurement disclosure?
- Alto Neuroscience (ANRO) reported fair value measurement disclosure of $2.34M in Q1 2026.
- How has Alto Neuroscience's fair value measurement disclosure changed year-over-year?
- Alto Neuroscience's fair value measurement disclosure increased by 92.8% year-over-year, from $1.21M to $2.34M.
- What is the long-term trend for Alto Neuroscience's fair value measurement disclosure?
- Over 2 years (2023 to 2025), Alto Neuroscience's fair value measurement disclosure has grown at a 28.3% compound annual growth rate (CAGR), from $1.35M to $2.23M.
- What does fair value measurement disclosure mean?
- This represents the aggregate carrying amount of assets and liabilities that are measured at fair value on a recurring or non-recurring basis. It provides transparency into the valuation techniques and inputs used to determine these values, categorized by the fair value hierarchy. This is critical for asset managers holding diverse investment portfolios.